FLAME试验:前列腺癌外照射放疗后肛直肠剂量与晚期胃肠道毒性的剂量效应关系
本研究基于III期FLAME试验所有患者(不论治疗臂),分析肛直肠照射剂量参数(D2cm3和D50%)与随访4年内≥2级胃肠道毒性的关系。采用重复测量混合模型分析并校正年龄、心血管疾病、糖尿病、T分期、基线毒性≥1级、激素治疗和机构。结果显示D2cm3和D50%均与胃肠道毒性存在剂量效应关系,校正OR分别为1.17(95%CI 1.13-1.21,p<0.0001)和1.20(95%CI 1.14-1.25,p<0.0001)。
要点
- 肛直肠D2cm3和D50%均与≥2级胃肠道毒性显著相关。
- 校正后OR分别为1.17和1.20,提示剂量越高毒性风险越大。
- 研究臂间毒性无差异,但肛直肠剂量增加需权衡局灶加量获益。
核心结论
- 尽管FLAME试验研究臂间毒性无差异,肛直肠接受更高放疗剂量与前列腺癌外照射后胃肠道毒性显著增加相关。
- 该剂量效应关系在大和小肛直肠体积参数上均存在。
- 进一步增加肛直肠剂量应权衡前列腺癌局灶剂量提升的获益。
研究设计与样本
- 基于III期FLAME试验(NCT01168479)所有患者的分析,不论治疗臂。
- 评估肛直肠剂量参数(D2cm3和D50%)与随访4年内≥2级胃肠道毒性的剂量效应关系。
- 采用重复测量混合模型分析,校正年龄、心血管疾病、糖尿病、T分期、基线毒性≥1级、激素治疗和机构。
主要发现
- D2cm3与胃肠道毒性的校正OR为1.17(95%CI 1.13-1.21,p<0.0001)。
- D50%与胃肠道毒性的校正OR为1.20(95%CI 1.14-1.25,p<0.0001)。
- 剂量效应关系在大和小肛直肠体积参数上均存在。
关键数值与推荐
- 肛直肠D2cm3每单位增加的校正OR为1.17(95%CI 1.13-1.21,p<0.0001),对应≥2级胃肠道毒性。
- 肛直肠D50%每单位增加的校正OR为1.20(95%CI 1.14-1.25,p<0.0001),对应≥2级胃肠道毒性。
临床怎么用
- 前列腺癌外照射放疗计划时应关注肛直肠D2cm3和D50%,以降低≥2级胃肠道毒性风险。
- 考虑前列腺局灶剂量提升时,需权衡肛直肠剂量增加带来的胃肠道毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The phase III FLAME trial (NCT01168479) showed an increase in five-year biochemical disease-free survival, with no significant increase in toxicity when adding a focal boost to external beam radiotherapy (EBRT) for localized prostate cancer [Kerkmeijer et al. JCO 2021]. The aim of this study was to investigate the association between delivered radiation dose to the anorectum and gastrointestinal (GI) toxicity (grade ≥2). MATERIAL AND METHODS: All patients in the FLAME trial were analyzed, irrespective of treatment arm. The dose-effect relation of the anorectal dose parameters (D2cm3 and D50%) and GI toxicity grade ≥2 in four years of follow-up was assessed using a mixed model analysis for repeated measurements, adjusted for age, cardiovascular disease, diabetes mellitus, T-stage, baseline toxicity grade ≥1, hormonal therapy and institute. RESULTS: A dose-effect relation for D2cm3 and D50% was observed with adjusted odds ratios of 1.17 (95% CI 1.13-1.21, p < 0.0001) and 1.20 (95% CI 1.14-1.25, p < 0.0001) for GI toxicity, respectively. CONCLUSION: Although there was no difference in toxicity between study arms, a higher radiation dose to the anorectum was associated with a statistically significant increase in GI toxicity following EBRT for prostate cancer. This dose-effect relation was present for both large and small anorectal volumes. Therefore, further increase in dose to the anorectum should be weighed against the benefit of focal dose escalation for prostate cancer.
引用
- Groen VH, Zuithoff NPA, van Schie M, et al. Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol. 2021. PMID: 34214614. doi:10.1016/j.radonc.2021.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。